Galena Biopharma (GALE) +11.7% premarket on news of the issuance of a key patent covering the...

|About: Galena Biopharma, Inc. (GALE)|By:, SA News Editor

Galena Biopharma (GALE) +11.7% premarket on news of the issuance of a key patent covering the use of its NeuVax product candidate for breast cancer patients having low-to-intermediate IHC levels, which represent a significant unmet medical need with as much as 80% of patients who do not qualify for Herceptin therapy.